---
created: 2025-04-13
updated: 2025-04-13T10:53
id: PU-,_0@BLY
specialty: pharmaco
specialty_id: 491
tags:
  - source/ak-original-decks::step-1::lolnotacop::drugs
  - "source/ak-step1-v11:": 
  - theme/amboss
  - "source/ak-step1-v11:": 
  - theme/b&b::11-hematology::04-cancer-drugs::06-other-cancer-drugs
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies::cetuximab
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::21-cetuximab-panitumumab
  - "source/ak-step1-v11:": 
  - source/ome-banner
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::17-hem/onc-pharm::rituximab-bevacizumab-alemtuzumab-cetuximab-panitumumab-trastuzmab
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::11-oncology::cetuximab,-panitumumab
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::08-antineoplastics::03-kinase-inhibitors-&-monoclonal-antibodies::02-rituximab,-cetuximab,-bevacizumab,-alemtuzumab,-trastuzumab
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::12000-12999::12049
  - source/ak-step1-v11::^other::^fa-updates::fa2019"
type: flashcard
---

# Question
Cetuximab is an antitumor monoclonal antibody that targets **EGFR**

---

# Answer
efficacy depends on the wild-type x mutated KRAS, the latter promotes resistance to this tx FA 2019: also lists panitumumab